Hermetica Superfood Encyclopedia
The Short Answer
Cinchona bark contains a suite of quinoline alkaloids—primarily quinine (6–16% of bark dry weight), quinidine, cinchonidine, and cinchonine—which exert antimalarial activity principally by accumulating in the food vacuole of Plasmodium parasites, inhibiting heme polymerization and causing toxic heme buildup that kills the parasite. Quinine derived from Cinchona officinalis was the dominant pharmacological treatment for Plasmodium falciparum malaria for over three centuries, with quinidine additionally demonstrating Class Ia antiarrhythmic efficacy in cardiac applications validated by mid-20th-century clinical pharmacology.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordcinchona bark benefits
Cinchona — botanical close-up
Health Benefits
**Antimalarial Activity**
Quinine, the primary alkaloid at 6–16% of bark content, accumulates in the acidic food vacuole of Plasmodium spp. and inhibits hemozoin (beta-hematin) formation, leading to toxic free heme accumulation that kills the intraerythrocytic parasite; this mechanism underpinned cinchona bark's centuries-long use as the principal malaria treatment before synthetic drugs emerged.
**Cardiac Antiarrhythmic Effect**: Quinidine, present at 0
25–3.0% of bark content, functions as a Class Ia antiarrhythmic agent by blocking fast sodium channels and prolonging cardiac action potential duration, and remains an FDA-approved therapy for certain ventricular and supraventricular arrhythmias.
**Anti-inflammatory Properties**
The alkaloid 3-hydroxy-4-(3-hydroxyphenyl)-2(1H)-quinolinone, identified at approximately 11.95% of isolated compounds, suppresses inflammatory signaling through inhibition of the NF-κB pathway in lipopolysaccharide-stimulated cells, reducing downstream pro-inflammatory cytokine expression.
**Antioxidant Activity**
Cinchona alkaloid fractions exhibit concentration-dependent free-radical scavenging against DPPH radicals, with reported EC50 values of 8.08 µg/mL and 64.19 µg/mL, and the ethyl acetate fraction demonstrating IC50 values of 17.63–23.57 µg/mL; 2,4-di-tert-butylphenol (12.24% of isolated compounds) further contributes antioxidant capacity.
**Digestive Bitter Tonic**
Cinchona bark has been used as a herbal bitter to stimulate digestive secretions via activation of bitter taste receptors (TAS2Rs) on enteroendocrine cells, promoting gastric acid and bile production to support appetite and digestion; this application underlies its historical inclusion in aperitif beverages such as tonic water and Campari.
**Antipyretic and Analgesic Effects**
Quinine historically demonstrated fever-reducing properties through central thermoregulatory mechanisms and mild analgesic activity, making cinchona bark one of the earliest pharmacological antipyretics documented in Western medicine, predating aspirin by over two centuries.
**Cytotoxic Potential Against Cancer Cells**
Preliminary in vitro research has documented cytotoxic effects of Cinchona alkaloid fractions against MCF-7 human breast cancer cells, suggesting that quinoline scaffold compounds may interfere with tumor cell proliferation, though this evidence is strictly preclinical and no human data currently support an oncological application.
Origin & History
Natural habitat
Cinchona officinalis is native to the eastern slopes of the Andes mountains in South America, particularly in Ecuador, Peru, Bolivia, and Colombia, thriving at elevations between 1,500 and 3,000 meters in montane cloud forests. The tree belongs to the family Rubiaceae and has been cultivated extensively in colonial-era plantations in Java (Indonesia), India, and parts of Africa to meet global pharmaceutical demand for quinine. Cultivation favors well-drained, humus-rich soils with high humidity and moderate temperatures; the bark is harvested from trunks and branches of mature trees typically 6–10 years old.
“Cinchona bark, known historically as 'Peruvian bark,' 'Jesuit's bark,' or 'quinquina,' was introduced to European medicine in the early 17th century, with accounts suggesting Spanish missionaries or Jesuits transported it from Peru to Europe around 1630–1640; it rapidly displaced all prior treatments for malaria (then called 'ague' or 'intermittent fever') and became one of the most economically and medically significant botanical commodities of the colonial era. Indigenous Andean peoples of the Quechua nation reportedly used the bark for its fever-relieving properties before European contact, and the name 'quinine' is widely believed to derive from the Quechua word 'kina' or 'quina,' meaning bark. The alkaloid quinine was first isolated in pure form in 1820 by French chemists Pierre Joseph Pelletier and Joseph Bienaimé Caventou, marking a foundational moment in the history of pharmaceutical chemistry and the beginning of the alkaloid isolation era. During World War II, when Japanese forces cut off Allied access to Javanese cinchona plantations, the urgent need to synthesize quinine alternatives directly accelerated development of chloroquine and other synthetic antimalarials, illustrating cinchona's pivotal role in shaping modern pharmacology.”Traditional Medicine
Scientific Research
The antimalarial pharmacology of Cinchona-derived quinine is among the most extensively characterized in medical history, supported by decades of controlled clinical trials, pharmacokinetic studies, and WHO treatment guidelines; quinine remains on the WHO Model List of Essential Medicines for severe malaria, and its efficacy against chloroquine-resistant Plasmodium falciparum has been established through randomized controlled trials conducted across sub-Saharan Africa and Southeast Asia. Quinidine's cardiac antiarrhythmic activity has been validated in multiple placebo-controlled and comparative trials, and the compound holds FDA approval, though meta-analyses have raised concerns about increased all-cause mortality relative to placebo in certain arrhythmia populations. Modern phytochemical and in vitro studies of C. officinalis specifically (as distinct from quinine pharmaceutical isolates) remain limited; available evidence consists primarily of DPPH antioxidant assays, cytotoxicity screens on MCF-7 cells, and NF-κB pathway analyses—none of which have been translated into human clinical trials with quantified patient outcomes. There is a meaningful evidentiary gap between the well-established pharmacology of isolated quinine/quinidine and the broader biological activity of the whole Cinchona bark extract, and no large-scale RCTs have evaluated standardized Cinchona bark extract as a dietary supplement in healthy populations.
Preparation & Dosage
Traditional preparation
**Pharmaceutical Quinine Sulfate (Tablets/Capsules)**
648 mg every 8 hours for 7 days (adult dosing for uncomplicated P
falciparum malaria per CDC guidelines); always co-administered with doxycycline or clindamycin in current clinical protocols.
**Quinidine Gluconate (IV/Oral)**
10 mg/kg IV loading dose over 1–2 hours, followed by 0
For severe malaria, .02 mg/kg/min continuous infusion under cardiac monitoring; oral cardiac dosing historically 200–400 mg three to four times daily under medical supervision.
**Cinchona Bark Dry Extract (Standardized Supplement)**
15–70 mg total quinoline alkaloids per dose; typical commercial preparations suggest 200–500 mg dried bark equivalent daily, though clinical evidence for these dosages is absent
No universally accepted standardization exists; some European herbal products standardize to .
**Tincture (1
1–3 mL three times daily before meals as a digestive bitter; quinine content per dose is pharmacologically low (well below therapeutic antimalarial concentrations)
5 in 60% ethanol)**: Traditional European pharmacopeial preparation dosed at .
**Decoction (Traditional South American Preparation)**
10–15 g dried bark per liter) and consumed as a tea; alkaloid extraction efficiency is lower than alcohol-based preparations due to limited water solubility of free-base alkaloids
Bark is simmered in water (approximately .
**Tonic Water (Dietary)**
83 mg quinine per liter by FDA regulation—a subtherapeutic concentration insufficient for malaria prophylaxis but sufficient to impart bitter flavor
Commercial tonic water in the United States contains a maximum of .
**Timing Note**
Bitter tonic preparations are most effective when consumed 15–30 minutes before meals to maximize cephalic-phase digestive secretion stimulation.
Nutritional Profile
Cinchona bark's pharmacological value lies in its alkaloid and phytochemical matrix rather than conventional macronutrient content, which is typical of a dried woody bark: negligible lipid and protein content, with fiber constituting the primary structural component. Total alkaloid concentration in the bark ranges from 6 to 15% dry weight across species, dominated by quinine (6–16%), with quinidine, cinchonidine, and cinchonine each contributing 0.25–3.0%. Tannins are a major secondary constituent at 3–10% dry weight, contributing astringency and exhibiting protein-binding properties that may reduce absorption of co-administered compounds; phenolic acids, flavonoids, glycosides, saponins, steroids, and terpenoids are present at lower but pharmacologically meaningful concentrations. Bioavailability of quinine from bark preparations is subject to the tannin matrix—tannin-alkaloid complexation can reduce alkaloid dissolution and absorption compared to pharmaceutical salt formulations, and first-pass hepatic metabolism (primarily CYP3A4-mediated) further limits systemic quinine availability from oral preparations.
How It Works
Mechanism of Action
Quinine and the related Cinchona quinoline alkaloids share a core pharmacophore centered on the nitrogen atom of the quinuclidine ring, which becomes protonated in the acidic environment of the Plasmodium food vacuole, trapping the drug intracellularly and raising local concentrations up to 100-fold above plasma levels; once concentrated, quinine intercalates with and inhibits the crystallization of toxic ferriprotoporphyrin IX (heme) into inert hemozoin, resulting in lethal oxidative membrane damage to the parasite. Quinidine acts at the cardiac sodium channel (Nav1.5) by binding the inactivated state of the channel, reducing maximal depolarization velocity (Vmax) in a use-dependent manner and prolonging both the effective refractory period and the QT interval through concurrent potassium channel (hERG/IKr) blockade. The anti-inflammatory alkaloid 3-hydroxy-4-(3-hydroxyphenyl)-2(1H)-quinolinone suppresses NF-κB nuclear translocation in macrophage-like cells exposed to LPS, thereby downregulating transcription of TNF-α, IL-6, and COX-2; antioxidant activity proceeds via hydrogen atom transfer and single-electron transfer mechanisms that neutralize DPPH, superoxide, and hydroxyl radicals.
Clinical Evidence
Clinical evidence for Cinchona-derived quinine in malaria treatment is robust and spans multiple WHO-endorsed RCTs; in trials of uncomplicated falciparum malaria, oral quinine (typically 10 mg/kg three times daily for 7 days) achieves parasite clearance rates exceeding 90% when combined with doxycycline or clindamycin, though monotherapy is associated with recrudescence. Quinidine sulfate has been evaluated in cardiac arrhythmia RCTs, but a 1990 meta-analysis (Coplen et al., JAMA) involving over 800 patients found significantly higher total mortality in quinidine-treated groups compared to controls, leading to its repositioning as a second-line agent. For non-pharmaceutical Cinchona bark extract applications—including antioxidant, anti-inflammatory, and digestive uses—no human RCTs with defined outcomes, sample sizes, or effect sizes have been published as of the most recent available literature. Confidence in the antimalarial application of the isolated alkaloid quinine is high (Level A evidence), while confidence in supplemental or whole-extract applications remains very low pending human trial data.
Safety & Interactions
Quinine and Cinchona alkaloids carry a well-documented adverse effect profile; at therapeutic antimalarial doses, cinchonism—characterized by tinnitus, headache, nausea, visual disturbances, and dizziness—is reported in up to 80% of patients and is dose-dependent and generally reversible upon discontinuation. Serious adverse effects include potentially fatal hypersensitivity reactions, immune-mediated thrombocytopenia, hemolytic uremic syndrome, and QT interval prolongation with risk of torsades de pointes cardiac arrhythmia, particularly at higher doses or in patients with underlying cardiac disease. Major drug interactions involve CYP3A4 and CYP2D6 inhibition: quinine elevates plasma concentrations of digoxin, warfarin (requiring INR monitoring), mefloquine (additive cardiac toxicity), and certain statins; co-administration with antacids containing aluminum or magnesium reduces quinine absorption; concurrent use with Class Ia or III antiarrhythmics is contraindicated due to additive QT prolongation risk. Cinchona bark preparations are contraindicated in pregnancy (quinine is teratogenic in animal studies and associated with uterine stimulation; FDA Category X for non-malarial use), in patients with G6PD deficiency (risk of hemolysis), myasthenia gravis, optic neuritis, or known hypersensitivity to quinoline compounds; lactation is also a contraindication for therapeutic doses as quinine is excreted in breast milk.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Quinine Tree (Cinchona spp.)Kina barkPeruvian barkRed cinchonaCinchona officinalisQuinquinaFever treeJesuit's bark
Frequently Asked Questions
What is cinchona bark used for medicinally?
Cinchona bark is most established as the original source of quinine, used for centuries to treat malaria caused by Plasmodium falciparum and other Plasmodium species; quinine works by accumulating in the parasite's food vacuole and blocking heme detoxification, killing the pathogen. Beyond malaria, the bark's alkaloid quinidine is used as a cardiac antiarrhythmic, and the whole bark has been employed as a digestive bitter tonic to stimulate gastric secretions and appetite.
Is cinchona bark safe to take as a supplement?
Cinchona bark at low doses found in traditional bitter tonic preparations (tinctures, aperitif beverages) is generally considered low-risk for healthy adults, but higher doses carry substantial risk of cinchonism—a syndrome of tinnitus, nausea, headache, and visual disturbances—as well as potentially fatal cardiac arrhythmias (QT prolongation) and immune-mediated thrombocytopenia. It is contraindicated during pregnancy, in patients with G6PD deficiency, myasthenia gravis, or those taking antiarrhythmic drugs, digoxin, or warfarin, and should not be self-administered for malaria treatment without medical supervision.
How much quinine is in cinchona bark?
Quinine is the dominant alkaloid in Cinchona officinalis bark, present at concentrations of approximately 6–16% of dry bark weight, though this varies considerably by species—Cinchona ledgeriana is highest (5–14% total alkaloids), while C. succirubra contains 5–7%. Commercial tonic water, by comparison, contains a maximum of 83 mg of quinine per liter under FDA regulations, which is far below the therapeutic antimalarial dose of 648 mg every 8 hours.
What are the side effects of cinchona or quinine?
At therapeutic doses, up to 80% of patients experience cinchonism: tinnitus, headache, dizziness, nausea, and blurred vision, which typically resolve after the drug is stopped. More serious risks include cardiac QT interval prolongation with potential for life-threatening torsades de pointes arrhythmia, immune thrombocytopenia, hemolytic anemia (especially in G6PD-deficient individuals), and rare but fatal hypersensitivity reactions; concurrent use with certain antibiotics, antifungals, and other QT-prolonging drugs markedly increases these risks.
Does cinchona bark still work against malaria today?
Pharmaceutical quinine derived from Cinchona alkaloids remains on the WHO Model List of Essential Medicines and is used for malaria treatment, particularly for severe or drug-resistant Plasmodium falciparum infections where it is typically co-administered with doxycycline or clindamycin to achieve parasite clearance rates exceeding 90%. However, raw cinchona bark preparations are not considered reliable for malaria treatment due to variable alkaloid content and absorption; standardized pharmaceutical formulations are required for safe and effective therapy, and self-treatment with bark supplements is medically inadvisable.
What is the difference between cinchona bark extract and quinine sulfate supplements?
Cinchona bark extract is a whole-plant preparation containing multiple alkaloids (quinine, quinidine, cinchonine, and cinchonidine) at varying concentrations, while quinine sulfate is an isolated and standardized form of the primary alkaloid. Quinine sulfate provides consistent dosing and pharmaceutical-grade purity, whereas cinchona bark extract may offer synergistic effects from multiple alkaloids but with less predictable alkaloid content. The choice between them depends on whether you seek the full botanical profile or a standardized, single-alkaloid approach.
Does cinchona interact with antimalarial medications or other common drugs?
Cinchona and its primary alkaloid quinine can interact with several medications, including cardiac drugs (like digoxin and antiarrhythmics), anticoagulants (such as warfarin), and certain antibiotics, potentially increasing side effects or reducing efficacy. Cinchona may also interact with medications metabolized by liver enzymes (CYP3A4 and CYP2D6), which could alter blood levels of these drugs. Anyone taking prescription medications should consult a healthcare provider before using cinchona supplements to avoid potentially serious interactions.
Why has cinchona use declined in modern medicine despite its historical success against malaria?
Cinchona's use declined due to the emergence of Plasmodium drug resistance to quinine, the development of synthetic antimalarials (like chloroquine and artemisinin derivatives) that are more effective and have better safety profiles, and improved malaria prevention through vector control and bed nets. Additionally, cinchona bark preparations have variable alkaloid content and higher risks of adverse effects compared to standardized synthetic drugs, making them less reliable for clinical use. Today, cinchona remains primarily of historical and ethnobotanical interest rather than a first-line malaria treatment.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cinchona-cinchona-officinalis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
